Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease

被引：0
|
作者：
Otto J. Visser
Lars R. Perk
Josée M. Zijlstra
Guus A.M.S. van Dongen
Peter C. Huijgens
Arjan A. van de Loosdrecht
机构：
[1] VU University Medical Center,Department of Hematology
[2] VU University Medical Center,Department of Otolaryngology/Head and Neck Surgery
来源：
BioDrugs | 2006年 / 20卷
关键词：
Autologous Stem Cell Transplantation; Bone Marrow Involvement; Bone Marrow Infiltration; Tositumomab; Ibritumomab Tiuxetan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Radioimmunotherapy (RIT) is a new treatment modality that combines the benefits of radiotherapy and immunotherapy. In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells. Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).
引用
收藏
页码：201 / 207
页数：6
相关论文
共 50 条
  • [41] Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma
    Naoto Fujita
    Ryoji Kobayashi
    Yoshiko Atsuta
    Fuminori Iwasaki
    Junji Suzumiya
    Yoji Sasahara
    Masami Inoue
    Katsuyoshi Koh
    Tsukasa Hori
    Hiroaki Goto
    Tatsuo Ichinohe
    Yoshiko Hashii
    Koji Kato
    Ritsuro Suzuki
    Tetsuo Mitsui
    [J]. International Journal of Hematology, 2019, 109 : 483 - 490
  • [42] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Yosuke Matsumoto
    Tsutomu Kobayashi
    Yuji Shimura
    Eri Kawata
    Hisao Nagoshi
    Muneo Ohshiro
    Mio Sugitani
    Kazuho Shimura
    Toshiki Iwai
    Shin-ichi Fuchida
    Mihoko Yoshida
    Miki Kiyota
    Shinsuke Mizutani
    Yoshiaki Chinen
    Tomoko Takimoto-Shimomura
    Mitsushige Nakao
    Hiroto Kaneko
    Hitoji Uchiyama
    Nobuhiko Uoshima
    Hikari Nishigaki
    Yutaka Kobayashi
    Shigeo Horiike
    Chihiro Shimazaki
    Masafumi Taniwaki
    Junya Kuroda
    [J]. International Journal of Hematology, 2019, 110 : 77 - 85
  • [43] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Matsumoto, Yosuke
    Kobayashi, Tsutomu
    Shimura, Yuji
    Kawata, Eri
    Nagoshi, Hisao
    Ohshiro, Muneo
    Sugitani, Mio
    Shimura, Kazuho
    Iwai, Toshiki
    Fuchida, Shin-ichi
    Yoshida, Mihoko
    Kiyota, Miki
    Mizutani, Shinsuke
    Chinen, Yoshiaki
    Takimoto-Shimomura, Tomoko
    Nakao, Mitsushige
    Kaneko, Hiroto
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Nishigaki, Hikari
    Kobayashi, Yutaka
    Horiike, Shigeo
    Shimazaki, Chihiro
    Taniwaki, Masafumi
    Kuroda, Junya
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (01) : 77 - 85
  • [44] Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma
    Fujita, Naoto
    Kobayashi, Ryoji
    Atsuta, Yoshiko
    Iwasaki, Fuminori
    Suzumiya, Junji
    Sasahara, Yoji
    Inoue, Masami
    Koh, Katsuyoshi
    Hori, Tsukasa
    Goto, Hiroaki
    Ichinohe, Tatsuo
    Hashii, Yoshiko
    Kato, Koji
    Suzuki, Ritsuro
    Mitsui, Tetsuo
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (04) : 483 - 490
  • [45] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
  • [46] Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Tobinai, K
    Watanabe, T
    Ogura, M
    Morishima, Y
    Ogawa, Y
    Ishizawa, KI
    Minami, H
    Utsunomiya, A
    Taniwaki, M
    Terauchi, T
    Nawano, S
    Matsusako, M
    Matsuno, Y
    Nakamura, S
    Mori, S
    Ohashi, Y
    Hayashi, M
    Seriu, T
    Hotta, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 174 - 180
  • [47] Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    Tobinai, Kensei
    Ishizawa, Ken-ichi
    Ogura, Michinori
    Itoh, Kuniaki
    Morishima, Yasuo
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Yamamoto, Joji
    Uchida, Toshiki
    Nakata, Masanobu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Hayashi, Masaki
    Hotta, Tomomitsu
    [J]. CANCER SCIENCE, 2009, 100 (10) : 1951 - 1956
  • [48] Radioimmunotherapy: A novel treatment modality for B-cell non-Hodgkin's lymphoma
    Juweid, M
    DeNardo, GL
    Graham, M
    Vose, J
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (05) : 673 - 674
  • [49] Radioimmunotherapy: A new treatment modality for B-cell non-Hodgkin's lymphoma
    Ghobrial, Irene
    Witzig, Thomas
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (05): : 623 - 630
  • [50] Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    Gordon, LI
    Wiseman, GA
    Spies, S
    Emmanouilides, C
    Czuczman, MS
    Flinn, IW
    Barlett, NL
    Murray, JL
    Alkuzweny, B
    Multani, PS
    Grillo-López, AJ
    White, CA
    [J]. BLOOD, 2000, 96 (11) : 731A - 731A
12345